Skip to search formSkip to main contentSkip to account menu

ARRY-334543

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

QuinazolinesThiazolesVarlitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
In vivoactivity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
Abstract #2150 ARRY-543 is an orally active, potent small molecule tyrosine kinase inhibitor targeting both EGFR and ErbB2. The… 
2009
2009
Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study
ARRY-334543 is an oral, potent, ATP-competitive, selective, reversible inhibitor of ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4… 
2009
2009
Abstract #1757: In vivo activity of ARRY-334543, a potent, small molecule inhibitor of EGFR/ErbB2 in combination with trastuzumab or docetaxel
ARRY-334543 is an orally active, potent small molecule tyrosine kinase inhibitor targeting both EGFR and ErbB2. The compound is a… 
2005
2005
ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2
3399 The growth factor receptor tyrosine kinases EGFR (ErbB-1) and ErbB-2 (HER-2/neu) play a major role in controlling cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)